Scholars Central

Conference abstract

TauRx global phase 3 trial in Alzheimer?s disease with tau aggregation inhibitor LMTX

Authors: Claude M Wischik

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

There have been 19 phase 2/3 clinical trial failures in 15,000 AD subjects to date, all aiming to reduce amyloid pathology. The Tau theory has offered an entirely viable alternative conceptual framework, largely ignored for the last 20 years. The filaments of the Alzheimer neurofibrillary tangle are made of a truncated fragment from the repeat domain of tau. This truncated fragment can catalyse the conversion of normal soluble tau into aggregated oligomeric and fibrillary forms which, in turn, can infect neighbouring neurons. Initiation of tau aggregation requires it?s binding to a non-specific substrate to expose a high affinity tau-tau binding domain and is self-propagating thereafter. The initiating complex is most likely formed as a consequence of age-related degradation of endosomal-lysosomal processing (ELP) of neuronal proteins, particularly of membrane proteins from mitochondria. Tau pathology begins in the late 40s and affects 50% of the population over the age of 45. Unlike amyloid load, Tau pathology is highly correlated with cognitive decline in post-mortem epidemiological studies and with FDG-PET imaging deficits, correlations also confirmed with new tau-selective PET ligands. Methylthioninium (MT), the first identified Tau Aggregation Inhibitor (TAI), reverses the proteolytic stability of the tau oligomers/filaments, facilitates their proteolytic clearance and reduces the load of tau pathology in transgenic tau mouse models. A phase 2 clinical trial in 321 subjects with mild/moderate AD demonstrated a reduction of 85%?30% in the rate of disease progression as measured by ADAS-cog over 12 months and prevented progression of functional imaging deficits. The chloride salt of oxidized MT (MTC) has dose-dependent pharmaceutical limitations. A superior stabilized reduced version of the molecule (leuco-MT, LMTX) has been developed, that has greater tolerability and better absorption at higher doses. Two global phase 3 trials are currently underway in 22 countries. Recruitment of the 1,500 subjects in these trials is expected to be completed by 3rd quarter of 2014, with first data read-out in 2016.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalGerontology & Geriatric Research
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Claude M Wischik”